Exelixis

EXEL · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

EXEL · Last close · October 26, 2026

$65.11

Exelixis' revenue rose 7.0% to $2.3 billion in fiscal 2025. Its operating margin was 37.6%, up from 27.9% a year earlier. Free cash flow was $876 million, up 30.4%. It paid out $948 million in dividends and buybacks, 108% of free cash flow. The diluted share count fell 4.8%.

Exelixis Inc Latest fiscal year ended January 2, 2026 10-K filed February 10, 2026 · 0000939767-26-000021 Updated October 14, 2026

Revenue

$2.3B

7.0%

Operating margin

37.6%

9.7 pts

Net income

$783M

50.1%

Free cash flow

$876M

30.4%

Return on capital

64.9%

26.4 pts

Market cap

$16.9B

Oct 26 close

P/E

20.5x

On $3.18 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Revenue and margins

Revenue

US$ billions, fiscal years

Margins

Percent of revenue

GrossOperatingNetFree cash flow

Net income and earnings per share

From fiscal 2017 to 2025, earnings per share grew 24.2% a year and net income 22.5% a year, as buybacks cut the share count by 10%.

Net income

US$ billions, fiscal years; loss years in red.

Diluted earnings per share

US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity

Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.

Return on capitalReturn on equity

Cash flow

Free cash flow

US$ billions. Cash from operations minus capital expenditure; negative years in red.

Payouts and share count

Dividends and buybacks

US$ billions, cash paid in each fiscal year

DividendsShare buybacks

Diluted share count

Weighted-average diluted shares, millions

Valuation

Two ways to value Exelixis yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.

Discounted cash flow (DCF)

A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Exelixis' 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.

Value per share on three example scenarios, from Exelixis' fiscal 2025 free cash flow of $876M, net cash of $1.1B at January 2, 2026 and 282 million diluted shares, from its filings. The scenarios are fitted to Exelixis: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 12.9% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 11% for a cyclical or higher-risk business (Biotechnology); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

From the filings

Starting free cash flow, US$ millions

Cash from operations minus capital spending in fiscal 2025.

Net cash, US$ millions Cash and short-term investments minus debt and finance leases at January 2, 2026. Negative means net debt.

Diluted shares, millions

Weighted-average diluted shares in fiscal 2025.

Your assumptions

Start from

Fitted to Exelixis's own revenue growth, as above. Cautious: growth of 6.5% then 4% a year, 2% after year 10, a 12% discount rate. Base: growth of 13% then 8% a year, 2.5% after year 10, a 11% discount rate. Optimistic: growth of 19.5% then 11% a year, 3% after year 10, a 10% discount rate.

Free cash flow growth, years 1 to 5 (% a year)

Free cash flow growth, years 6 to 10 (% a year)

Growth after year 10 (% a year)Long-run growth forever after year 10. Usually close to inflation, and always below the discount rate.

Discount rate (% a year)The yearly return an investor wants for the risk. A higher rate gives a lower value.

Value per share on these assumptions

—

Last close, October 26, 2026: $65.11
Value on these assumptions, against the last close: —

Cash flows in years 1 to 10, valued today: —
Everything after year 10, valued today: —
Plus net cash: —
Share of value from after year 10: —

Projected free cash flow

US$ billions. Each column is one year's projected free cash flow, split into what it is worth today and the part removed by discounting.

Value todayRemoved by discounting

How the value changes with two assumptions

Value per share in US$, with the growth rates above. The highlighted cell matches the current assumptions.

How the model works. Free cash flow grows at the first rate for five years and the second rate for five more, and each year is discounted at the discount rate. Everything after year 10 is valued as year-10 cash flow × (1 + growth after year 10) ÷ (discount rate − growth after year 10), discounted back ten years. Net cash is added and the total is divided by diluted shares. The result depends entirely on the assumptions. It is not a forecast, a price target or a recommendation. The last close is the consolidated US closing price, from Databento.

Price-to-earnings (P/E) method

Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.

Value per share on three example scenarios, from Exelixis' earnings per share of $3.18 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 24.2×, the average of the Health Care median and Exelixis' own P/E today for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 12%, 11% and 10%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

Earnings per share, US$

Diluted earnings per share over the four quarters to July 3, 2026, from the 10-Qs and 10-K.

P/E multiple

P/E today is the last close divided by the latest earnings per share, the four quarters' where available. Peers: Neurocrine Biosciences.

Earnings growth in the years ahead (% a year) Starts at Exelixis' revenue growth over the last 3 years, 12.9% a year, as the base scenario does.

Earnings per share in the years ahead, US$

Year 1Year 2Year 3Year 4Year 5

Type your own estimate for any year; the years after it carry on at the growth rate.

Apply the multiple to earnings

A multiple on a future year's earnings gives the price then, brought back to today at the discount rate below.

Discount rate (% a year) The yearly return an investor wants for the risk, as in the cash flow model.

Value per share today at this multiple

—

Last close, October 26, 2026: $65.11
Value at this multiple, against the last close: —
Exelixis' P/E at the last close: 20.5×

Company	Last close	Earnings per share	P/E today
Neurocrine BiosciencesNBIX	$145.87	$6.82	21.4×
ExelixisEXEL	$65.11	$3.18	20.5×

How the P/E method works. Value per share is earnings per share times the multiple. On a future year's earnings, that gives the price in that year, which is brought back to today at the discount rate: price ÷ (1 + discount rate) for each year ahead. It is quick and easy to compare across companies, but it ignores debt and cash, and earnings can swing with one-off gains and charges, so a multiple says most about steady, profitable businesses. Like the cash flow model, the result depends entirely on the assumptions you choose. It is not a forecast, a price target or a recommendation.

Balance sheet

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	1,467	1,308	995	1,111	1,059
Debt incl. finance leases	0	0	0	0	0
Net debt (negative means net cash)	−1,467	−1,308	−995	−1,111	−1,059
Net debt to EBITDA	−4.9x	−5.9x	−5.1x	−1.8x	−1.2x
Debt to equity	0.0x	0.0x	0.0x	0.0x	0.0x
Interest coverage	—	—	—	—	—
Current ratio	5.4x	5.0x	3.3x	3.6x	3.6x
Quick ratio	5.3x	4.9x	3.3x	3.6x	3.5x

US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Insider trades

Over the 12 months between October 27, 2025 and October 26, 2026, 1 insider bought $1.2 million of Exelixis shares on the open market, and 12 insiders sold $42.2 million, $6.9 million of it under trading plans set up in advance.

Date	Insider	Trade	Shares	Price	Value	Filing
Aug 10, 2026	Mary C BeckerleDirector	Sold plan	9,812	$53.66	$526,512	Form 4
Jun 1, 2026	Sue Gail EckhardtDirector	Sold plan	9,812	$50.14	$491,974	Form 4
Jun 1, 2026	Jack L WyszomierskiDirector	Sold plan	3,925	$50.55	$198,409	Form 4
May 26, 2026	Dana AftabEVP, Research and Development	Sold	43,451	$50.35	$2.2 million	Form 4
May 20, 2026	Patrick J. HaleyEVP, Commercial	Sold	32,110	$49.81	$1.6 million	Form 4
May 18, 2026	Christopher J. SennerEVP and CFO	Sold	34,901	$50.00	$1.7 million	Form 4
May 18, 2026	Brenda HeftiSVP and General Counsel	Sold plan	6,625	$50.21	$332,641	Form 4
May 7, 2026	George PosteDirector	Sold	60,000	$45.71	$2.7 million	Form 4
May 7, 2026	Maria C FreireDirector	Sold	20,634	$46.00	$949,164	Form 4
May 7, 2026	Mary C BeckerleDirector	Sold	7,712	$48.45	$373,646	Form 4
Feb 24, 2026	Dana AftabEVP, Research and Development	Sold	47,918	$44.50	$2.1 million	Form 4
Feb 19, 2026	Dana AftabEVP, Research and Development	Sold	29,873	$44.35	$1.3 million	Form 4

The latest 12 of 27 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Piotroski F-score

The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.

Test	FY23	FY24	FY25
Net income is positive	Pass	Pass	Pass
Cash from operations is positive	Pass	Pass	Pass
Return on assets rose	Fail	Pass	Pass
Cash from operations exceeds net income	Pass	Pass	Pass
Debt fell relative to assets	Fail	Fail	Fail
Current ratio rose	Fail	Pass	Fail
Share count didn't rise	Pass	Pass	Pass
Gross margin rose	Fail	Pass	Fail
Revenue rose relative to assets	Fail	Pass	Pass
F-score	4 of 9	8 of 9	6 of 9
Accruals ratio	−4.2%	−6.1%	−3.5%

The accruals ratio is net income minus cash from operations, over average total assets.

Compare

Put Exelixis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

Company	Year	Revenue growth	Operating margin	Free cash flow margin	Return on capital	Net debt to EBITDA	F-score	Compare
Exelixis	FY25	7.0%	37.6%	37.8%	64.9%	−1.2x	6
Fortrea	FY25	1.0%	−32.0%	3.2%	−36.2%	—	—	Compare
Moderna	FY25	−39.9%	−158.1%	−106.2%	−65.4%	—	2	Compare
Neurocrine Biosciences	FY25	21.4%	21.6%	26.2%	25.6%	−2.3x	6	Compare
BioNTech	FY25	4.3%	−49.0%	9.8%	—	—	—	Compare

Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score above.

10 years of figures

Fiscal year	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Revenue	192	452	854	968	988	1,435	1,611	1,830	2,169	2,320
Revenue growth	415.1%	136.3%	88.7%	13.3%	2.0%	45.3%	12.3%	13.6%	18.5%	7.0%
Gross profit	185	437	828	935	951	1,382	1,553	1,758	2,092	2,236
Research and development	96	112	182	337	548	694	892	1,044	910	825
Operating income	−28	166	439	370	110	287	202	171	605	872
Net income	−70	154	690	321	112	231	182	208	521	783
Diluted EPS (US$)	−0.28	0.49	2.21	1.02	0.35	0.72	0.56	0.65	1.76	2.78
Diluted shares (millions)	250	312	313	315	318	322	325	322	296	282
Cash flow
Cash from operations	206	166	416	527	209	401	363	333	700	884
Capital expenditure	2	21	33	13	30	54	28	40	28	8
Free cash flow	205	144	382	514	179	347	335	293	672	876
Dividends paid	0	0	0	0	0	0	0	0	0	0
Share buybacks	0	0	0	0	0	0	0	550	652	948
Acquisitions	0	0	0	0	0	0	0	0	0	0
Stock-based compensation	23	24	41	57	105	120	108	106	94	113
Balance sheet at fiscal year end
Cash and short-term investments	420	388	693	852	1,206	1,467	1,308	995	1,111	1,059
Debt incl. finance leases	189	0	0	0	0	0	0	0	0	0
Total assets	598	655	1,422	1,886	2,137	2,616	3,072	2,942	2,948	2,844
Total liabilities	508	370	135	200	258	406	583	678	704	683
Shareholders' equity	89	285	1,288	1,686	1,879	2,211	2,488	2,264	2,244	2,161
Margins and ratios
Gross margin	96.6%	96.7%	96.9%	96.6%	96.3%	96.3%	96.4%	96.0%	96.5%	96.4%
Operating margin	−14.7%	36.7%	51.4%	38.2%	11.1%	20.0%	12.5%	9.3%	27.9%	37.6%
Net margin	−36.7%	34.1%	80.8%	33.2%	11.3%	16.1%	11.3%	11.3%	24.0%	33.7%
Free cash flow margin	106.9%	31.9%	44.8%	53.1%	18.1%	24.1%	20.8%	16.0%	31.0%	37.8%
Return on capital	—	—	178.6%	41.7%	12.5%	31.8%	16.3%	11.3%	38.5%	64.9%
Return on equity	—	82.4%	87.8%	21.6%	6.3%	11.3%	7.8%	8.7%	23.1%	35.5%
Return on assets	−15.1%	24.6%	66.4%	19.4%	5.6%	9.7%	6.4%	6.9%	17.7%	27.0%
Net debt to EBITDA	—	−2.3x	−1.6x	−2.3x	−10.1x	−4.9x	−5.9x	−5.1x	−1.8x	−1.2x

US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)

Source: Exelixis' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Exelixis.